HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Tom R. Gaunt | Aroon D. Hingorani | J. Gallacher | M. Fornage | J. Manson | A. Reiner | D. Lawlor | S. Redline | H. Hakonarson | D. van der A | P. Ridker | D. Chasman | R. Krauss | N. Timpson | R. Schnabel | Yiran Guo | A. Gotto | J. McMurray | J. Lewsey | A. Keech | S. Humphries | D. Duggan | A. Hingorani | A. Algra | J. Coresh | B. Psaty | D. Siscovick | P. Talmud | P. Whincup | N. Sattar | L. Tavazzi | M. Marmot | S. Kathiresan | J. Whittaker | M. Kivimäki | R. Topor-Madry | S. Sharp | N. Wareham | A. Hamsten | U. de Faire | J. A. Delaney | D. Waters | J. Jukema | J. Robinson | W. Spiering | R. Westendorp | F. Dudbridge | G. Lowe | James G. Wilson | Philip N. Howard | G. Smith | R. Scott | C. Eaton | N. Forouhi | C. Langenberg | N. Poulter | P. Schreiner | P. Sever | P. van der Harst | Y. Ben-Shlomo | B. Sennblad | F. Veglia | J. Price | D. Baldassarre | E. Tremoli | A. Wong | M. Kumari | D. Kuh | I. Tzoulaki | E. Brunner | A. Amuzu | M. Bobák | R. Hardy | R. Kubínová | S. Malyutina | A. Pająk | H. Pikhart | A. Tamosiunas | W. Verschuren | P. Amarenco | M. Cushman | P. D. de Jong | N. Verweij | I. Ford | F. Asselbergs | G. D. de Borst | F. Drenos | L. Lange | A. Tybjaerg-hansen | M. Holmes | R. Morris | Y. T. van der Schouw | N. Onland-Moret | A. Maggioni | G. Tognoni | A. de Boer | Y. Li | J. Cooper | B. Keating | O. Klungel | J. Kjekshus | K. Kuchenbaecker | M. Voevoda | R. Sofat | C. Giambartolomei | Paul C D Johnson | M. Leusink | Marlene C. W. Stewart | J. Palmen | J. Hubacek | S. Buxbaum | J. Downs | T. Pedersen | P. Doevendans | S. Stender | A. Peasey | C. Dale | T. Shah | K. Ray | D. Preiss | Kawah Li | J. Engmann | D. Swerdlow | R. Hoogeveen | C. Chung | M. Baceviciene | B. A. Castillo | M. Tsai | R. Marchioli | S. Seshasai | Naveed Sattar | Daniel I. Swerdlow | David Preiss | U. Stepaniak | Anke H Maitland-van der Zee | H. Nakamura | S. Patel

[1]  D. Kim,et al.  1242: THE GOOD, THE BAD, AND, THE UNKNOWN , 2014 .

[2]  Tom S. Price,et al.  Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. , 2014, American journal of human genetics.

[3]  Michael J Pencina,et al.  Application of new cholesterol guidelines to a population-based sample. , 2014, The New England journal of medicine.

[4]  Andrew Steptoe,et al.  COHORT PROFILE Cohort Profile : The English Longitudinal Study of Ageing , 2014 .

[5]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[6]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[7]  Tara Gomes,et al.  Risk of incident diabetes among patients treated with statins: population based study , 2013, BMJ.

[8]  S. de Servi,et al.  Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. , 2013, The American journal of cardiology.

[9]  M. Hernán,et al.  Statins and Risk of Diabetes , 2013, Diabetes Care.

[10]  J. Berger,et al.  Statins and Diabetes: The Good, the Bad, and the Unknown , 2013, Current Atherosclerosis Reports.

[11]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[12]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[13]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[14]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[15]  Tanya M. Teslovich,et al.  Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways , 2012, Nature Genetics.

[16]  N. Sattar,et al.  Statins are diabetogenic--myth or reality? , 2012, Atherosclerosis. Supplements.

[17]  Tanya M. Teslovich,et al.  The Metabochip, a Custom Genotyping Array for Genetic Studies of Metabolic, Cardiovascular, and Anthropometric Traits , 2012, PLoS genetics.

[18]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[19]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[20]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[21]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[22]  S. McGuire.  Shields M., Carroll M.D., Ogden C.L. adult obesity prevalence in Canada and the United States. NCHS data brief no. 56, Hyattsville, MD: National Center for Health Statistics, 2011. , 2011, Advances in nutrition.

[23]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[24]  P. Barter,et al.  Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.

[25]  J. Danesh,et al.  Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data , 2011, BMJ : British Medical Journal.

[26]  D. Makuc,et al.  Health, United States, 2010; with special feature on death and dying , 2011 .

[27]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[28]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[29]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[30]  M. Quon,et al.  Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. , 2010, Journal of the American College of Cardiology.

[31]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[32]  C. White,et al.  Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. , 2010, Diabetes research and clinical practice.

[33]  Tanya M. Teslovich,et al.  Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index , 2010 .

[34]  Thomas Meitinger,et al.  Genetic Determinants of Circulating Sphingolipid Concentrations in European Populations , 2009, PLoS genetics.

[35]  Paul M. Ridker,et al.  Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.

[36]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[37]  Rebecca M Reynolds,et al.  The Edinburgh Type 2 Diabetes Study: study protocol , 2008, BMC endocrine disorders.

[38]  M. Daly,et al.  Common SNPs in HMGCR in Micronesians and Whites Associated With LDL-Cholesterol Levels Affect Alternative Splicing of Exon13 , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[39]  Mark I. McCarthy,et al.  Concept, Design and Implementation of a Cardiovascular Gene-Centric 50 K SNP Array for Large-Scale Genomic Association Studies , 2008, PloS one.

[40]  M. Tobin,et al.  Mendelian Randomisation and Causal Inference in Observational Epidemiology , 2008, PLoS medicine.

[41]  W. Feeman.  Statins and diabetes , 2008, The Lancet.

[42]  C. Meisinger,et al.  RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. , 2008, European journal of endocrinology.

[43]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[44]  Cholesterol Treatment Trialists' Collaborators.  Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[45]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[46]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[47]  P. Arora,et al.  Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. , 2008, The American journal of medicine.

[48]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[49]  R. Holman,et al.  Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial , 2008, Diabetologia.

[50]  D. Lawlor,et al.  Clustered Environments and Randomized Genes: A Fundamental Distinction between Conventional and Genetic Epidemiology , 2007, PLoS medicine.

[51]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[52]  A. Hofman,et al.  The Rotterdam Study: objectives and design update , 2007, European Journal of Epidemiology.

[53]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[54]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[55]  Thomas Meitinger,et al.  The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives , 2007, BMC Medical Genetics.

[56]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[57]  D. Kuh,et al.  Cohort Profile: The 1946 National Birth Cohort (MRC National Survey of Health and Development). , 2006, International journal of epidemiology.

[58]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[59]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[60]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005 .

[61]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[62]  Michael Marmot,et al.  Cohort Profile: the Whitehall II study. , 2005, International journal of epidemiology.

[63]  U. Laufs,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[64]  D. Betteridge,et al.  Statins and Diabetes , 2004, Seminars in vascular medicine.

[65]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[66]  J. Davignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[67]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[68]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[69]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[70]  D. Lawlor,et al.  Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study , 2003, Journal of epidemiology and community health.

[71]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[72]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[73]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[74]  S. Redline,et al.  Genetics of the apnea hypopnea index in Caucasians and African Americans: I. Segregation analysis , 2002, Genetic epidemiology.

[75]  Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[76]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[77]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[78]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[79]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[80]  S. Redline,et al.  The familial aggregation of obstructive sleep apnea. , 1995, American journal of respiratory and critical care medicine.

[81]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[82]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[83]  Gower Street,et al.  Health inequalities among British civil servants: the Whitehall II study , 1991, The Lancet.

[84]  R. Prescott,et al.  Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. , 1991, International journal of epidemiology.

[85]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[86]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[87]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[88]  A. Fehily,et al.  Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group. , 1984, Journal of epidemiology and community health.

[89]  M Walker,et al.  British regional heart study. , 1984, Nursing mirror.

[90]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.